J 2023

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

LJUNGMAN, Per; Gloria TRIDELLO; Jose Luis PINANA; Fabio CICERI; Henrik SENGELOEV et. al.

Základní údaje

Originální název

Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry

Autoři

LJUNGMAN, Per (garant); Gloria TRIDELLO; Jose Luis PINANA; Fabio CICERI; Henrik SENGELOEV; Alexander KULAGIN; Stephan MIELKE; Zeynep Arzu YEGIN; Matthew COLLIN; Sigrun EINARDOTTIR; Sophie Ducastelle LEPRETRE; Johan MAERTENS; Antonio CAMPOS; Elisabetta METAFUNI; Herbert PICHLER; František FOLBER (203 Česká republika, domácí); Carlos SOLANO; Emma NICHOLSON; Meltem Kurt YUEKSEL; Kristina CARLSON; Beatriz AGUADO; Caroline BESLEY; Jenny BYRNE; Immaculada HERAS; Fiona DIGNAN; Nicolaus KROEGER; Christine ROBIN; Anjum KHAN; Stig LENHOFF; Anna GRASSI; Veronika DOBSINSKA; Nuno MIRANDA; Maria-Jose JIMENEZ; Ipek YONAL-HINDILERDEN; Keith WILSON; Dina AVERBUCH; Simone CESARO; Alienor XHAARD; Nina KNELANGE; Jan STYCZYNSKI; Malgorzata MIKULSKA a de la Camara RAFAEL

Vydání

Frontiers in immunology, LAUSANNE, Frontiers Media S.A. 2023, 1664-3224

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.700

Kód RIV

RIV/00216224:14110/23:00130694

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000953835700001

EID Scopus

2-s2.0-85150496015

Klíčová slova anglicky

COVID-19; allogeneic; stem cell transplantation; CMV; risk factors

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 2. 5. 2023 10:02, Mgr. Tereza Miškechová

Anotace

V originále

IntroductionCOVID-19 has been associated with high morbidity and mortality in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. MethodsThis study reports on 986 patients reported to the EBMT registry during the first 29 months of the pandemic. ResultsThe median age was 50.3 years (min - max; 1.0 - 80.7). The median time from most recent HCT to diagnosis of COVID-19 was 20 months (min - max; 0.0 - 383.9). The median time was 19.3 (0.0 - 287.6) months during 2020, 21.2 (0.1 - 324.5) months during 2021, and 19.7 (0.1 - 383.9) months during 2022 (p = NS). 145/986 (14.7%) patients died; 124 (12.6%) due to COVID-19 and 21 of other causes. Only 2/204 (1%) fully vaccinated patients died from COVID-19. There was a successive improvement in overall survival over time. In multivariate analysis, increasing age (p<.0001), worse performance status (p<.0001), contracting COVID-19 within the first 30 days (p<.0001) or 30 - 100 days after HCT (p=.003), ongoing immunosuppression (p=.004), pre-existing lung disease (p=.003), and recipient CMV seropositivity (p=.004) had negative impact on overall survival while patients contracting COVID-19 in 2020 (p<.0001) or 2021 (p=.027) had worse overall survival than patients with COVID-19 diagnosed in 2022. DiscussionAlthough the outcome of COVID-19 has improved, patients having risk factors were still at risk for severe COVID-19 including death.